Direct‐acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens | Zendy

Toyoda Hidenori | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Direct‐acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens

Author(s) -

Toyoda Hidenori

Publication year - 2019

Publication title -

health science reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.462

H-Index - 7

ISSN - 2398-8835

DOI - 10.1002/hsr2.106

Subject(s) - ribavirin , regimen , ombitasvir , ritonavir , paritaprevir , medicine , genotype , hepatitis c virus , virology , chronic hepatitis , cirrhosis , dasabuvir , antiviral therapy , hepatitis c , virus , viral load , biology , antiretroviral therapy , biochemistry , gene

The optimal antiviral regimen for hepatitis C virus (HCV) genotype 4 is still a subject of investigation. The report in this issue of Health Science Reports by Asselah and colleagues investigated the additional benefit of extending treatment duration of the ombitasvir/paritaprevir/ritonavir plus ribavirin regimen to up to 24 weeks for patients with HCV genotype 4 and compensated cirrhosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research